Claims for Patent: 8,410,102

Summary for Patent: 8,410,102

Title:	Methods and compositions for treating or preventing erythema
Abstract:	Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one .alpha.-adrenergic receptor agonist and a pharmaceutically acceptable carrier.
Inventor(s):	Graeber; Michael (Lawrenceville, NJ), Loesche; Christian (Valbonne, FR), Freidenreich; Philip (Yardley, PA), Dejovin; Jack A. (New Brunswick, NJ), Dejovin; Isabelle Jean (New Brunswick, NJ), Liu; Yin-Sang (Princeton Junction, NJ), Leoni; Matthew James (Hampton, NJ)
Assignee:	Galderma Laboratories Inc. (Fort Worth, TX)
Application Number:	13/072,104
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,410,102
Patent Claims:	1. A method of treating erythema or a symptom associated therewith in a subject, the method comprising topically administering to a skin area of the subject a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one a adrenergic receptor agonist and a pharmaceutically acceptable carrier, wherein the skin area is, or is prone to be, affected by the erythema or the symptom associated therewith. 2. The method of claim 1, wherein the erythema is erythema of rosacea. 3. The method of claim 1, wherein the at least one .alpha.-adrenergic receptor agonist is an agonist selective for an .alpha.1-adrenergic receptor. 4. The method of claim 1, wherein the at least one .alpha.-adrenergic receptor agonist is an agonist selective for an .alpha.2-adrenergic receptor. 5. The method of claim 1, wherein the at least one .alpha.-adrenergic receptor agonist is a non-selective .alpha.-adrenergic receptor agonist. 6. The method of claim 1, wherein the at least one .alpha.-adrenergic receptor agonist is brimonidine. 7. The method of claim 1, wherein the at least one .alpha.-adrenergic receptor agonist is oxymetazoline. 8. The method of claim 1, wherein the at least one .alpha.-adrenergic receptor agonist is naphazoline. 9. The method of claim 1, wherein the at least one .alpha.-adrenergic receptor agonist is selected from the group consisting of tetrahydrozoline, xylometazoline, phenylephrine, methoxamine, mephentermine, metaraminol, midodrine, epinephrine and norepinephrine. 10. The method of claim 1, further comprising administering to the subject at least one additional treatment and medication for erythema or the symptom associated therewith. 11. The method of claim 1, wherein the topical aqueous gel composition is administered to the skin area once daily. 12. The method of claim 1, wherein the topical aqueous gel composition comprises about 0.20% (w/w) to about 4.0% (w/w) gelling agent. 13. The method of claim 1, wherein the topical aqueous gel composition comprises about 0.50% (w/w) to about 2.0% (w/w) carbomer.